This review outlines the anti-obesity effects and mechanisms of action of emerging anti-obesity drugs, including GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.